Table 3:
Differences in clinical and sociodemographic characteristics between respondents without and with financial burden (FB)
| No FB (n=64) | FB present (n=126) | p value | |
|---|---|---|---|
| Age at enrollment | 0.010 | ||
| Mean (SD) | 56 (14.2) | 51 (14) | |
| Race | 0.03 | ||
| White | 61 (95%) | 105 (83%) | |
| Others | 3 (5%) | 5 (17%) | |
| Gender | 1.000 | ||
| Male | 42 (66%) | 82 (65%) | |
| Income before transplant | 0.07 | ||
| <25,000 (low) | 2 (4%) | 16 (15%) | |
| $25,000–74,999 (medium) | 18 (32%) | 31 (30%) | |
| ≥75,000 (high) | 36 (64%) | 58 (55%) | |
| Income at survey | < 0.001 | ||
| <25,000 (low) | 3 (5%) | 34 (29%) | |
| $25,000–74,999 (medium) | 20 (35%) | 51 (43%) | |
| ≥75,000 (high) | 35(60%) | 34(29%) | |
| Education | 0.900 | ||
| Any college or higher | 46 (79%) | 92 (81%) | |
| No college | 12 (21%) | 21 (19%) | |
| Baseline employment status | 0.001 | ||
| Disabled/Unemployed | 13 (22%) | 58 (50%) | |
| Full/part-time | 25 (42%) | 31 (27%) | |
| Homemaker/retired | 21 (36%) | 26 (23%) | |
| Employment status at survey | < 0.001 | ||
| Disabled/Unemployed | 11 (17%) | 56 (44%) | |
| Full/part-time | 31 (48%) | 39 (31%) | |
| Homemaker/retired | 22 (34%) | 31 (25%) | |
| Insurance type | 0.061 | ||
| Medicare/ Medicaid | 17 (27%) | 50 (40%) | |
| Private | 40 (63%) | 55 (44%) | |
| Other | 7 (11%) | 19 (15%) | |
| Transplant source | 0.236 | ||
| Bone marrow | 4 (6%) | 10 (8%) | |
| Cord blood | 0 (0.0%) | 5 (4%) | |
| Peripheral blood | 60 (94%) | 110 (88%) | |
| Disease Diagnosis | 0.73 | ||
| Acute Leukemia | 29 (45%) | 63 (50%) | |
| CML/MDS/MPD | 16 (25%) | 33 (26%) | |
| Lymphoma including CLL | 15 (23%) | 21 (17%) | |
| AA/Other | 4 (6%) | 9 (7%) | |
| Disease status | 0.263 | ||
| Advanced | 7 (11%) | 25 (20%) | |
| Early | 34 (53%) | 56 (44%) | |
| Intermediate | 23 (36%) | 45 (36%) | |
| Conditioning | 0.262 | ||
| Myeloablative | 28 (44%) | 66 (52%) | |
| Reduced intensity | 16 (25%) | 34 (27%) | |
| Non-myeloablative | 20 (31%) | 26 (21%) | |
| SF-36 physical component score closest to survey completion | 0.004 | ||
| Mean (SD) | 42.5(9.6) | 38.2 (8.9) | |
| SF-36 mental component score closest to survey completion | 0.006 | ||
| Mean (SD) | 51.5 (9) | 46.4 (12.3) | |
| Modified adjusted activity score, closest to survey completion | 0.007 | ||
| Mean (SD) | 69.5 (13.3) | 63.5 (13.9) | |
| Comorbidity index, baseline | 0.848 | ||
| Median (Range) | 2 (0 – 7) | 2 (0–9) | |
| Chronic GVHD severity | 0.431 | ||
| Mild | 17 (27%) | 27 (22%) | |
| Moderate | 35 (57%) | 65 (54%) | |
| Severe | 10 (16%) | 29 (24%) | |
| Visit type | 0.157 | ||
| Clinic | 32 (50%) | 78 (62%) | |
| Mailed in | 32 (50%) | 48 (38%) | |
| Institution location | 0.779 | ||
| Canada | 6 (9%) | 15 (12%) | |
| United States | 58 (91%) | 111 (88%) | |
| Years from transplant to survey | 0.610 | ||
| Mean (SD) | 3.6 (2.2) | 3.5(2.6) | |
| Depression/anxiety/difficulty sleeping score | 0.004 | ||
| Mean (SD) | 15.7 (14.3) | 25.6 (23.9) |
Abbreviations: CML, chronic myelogenous leukemia; MDS, Myelodysplastic syndrome; MPD, Myeloproliferative disease; CLL, chronic lymphocytic leukemia; AA, Aplastic anemia; SD, standard deviation